13 August 2019Webinar: Obviousness of biologics inventions – strategies for biologics claims in the US, Europe and China
Thursday 5 September 20191:00 – 2:30pm (EDT) | 6:00 – 7:30pm (BST)Register here (early registration discount deadline Friday 16 August)Join Mathys & Squire Partner Hazel Ford and a panel of patent attorneys in this live webinar with interactive Q&A which will guide patent counsel through overcoming the challenges of obviousness in biologics patent claims in the US, Europe and China. The panel will examine the similarities and differences between claim types that have the best chance of success, and discuss recent case law and critical issues that arise.Eight of the top 10 best selling drugs last year were biologics. Unsurprisingly, patents relating to new biologics products are often challenged in patent offices and courts around the world, as well as the PTAB. At a time when global litigation is the norm, it is vital to understand and coordinate strategies around the world.Topics of discussion will include:The USPTAB treatmentCourt treatmentStrategies for overcoming obviousness challengesEuropeEPO treatmentCourt treatmentStrategies for overcoming obviousness challengesChinaAgency treatmentCourt treatmentStrategies for overcoming obviousness challengesThe following key issues will also be covered during the webinar:What evidence should counsel provide to support its assertion of nonobviousness in biologics patents?How can counsel overcome the inconsistency in the EPO’s treatment of biologics patents?How can patent counsel guide applicants during patent application drafting to reduce the likelihood of rejection?For more information and to register, click here.